EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy

Makoto Tahara, Darren Wan-Teck Lim, Bhumsuk Keam, Brigette Ma, Li Zhang, Chaojun Wang, Ye Guo

Cancer Treatment Reviews · 2025-05 · 136 · 102938

DOI: 10.1016/j.ctrv.2025.102938 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-05. Verfasst von Makoto Tahara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Recurrence, Local, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer globally. For patients with recurrent or metastatic (R/M) HNSCC, immunotherapy represents an important advance in clinical practice as an effective and widely used first-line treatment. However, drug resistance following immunotherapy is an emerging problem and, despite the success of immunotherapy in R/M HNSCC, a proportion of patients will become immunotherapy resistant. The mechanisms of immunotherapy resistance are not yet fully understood and subsequent treatment options are limited. Therefore, there is an unmet need for effective and well tolerated treatments for patients who develop immunotherapy-resistant HNSCC. In this review, we address these challenges by summarizing the current definitions of immunotherapy resistance (primary and acquired resistance) as well as knowledge of the mechanisms of resistance to immunotherapy in R/M HNSCC. We then review available clinical data on treatment strategies, including rechallenge with immunotherapy, chemotherapy ± cetuximab, other targeted treatments, antibody-drug conjugates, and bispecific antibodies. We also investigate future research directions by reviewing ongoing clinical trials. Our review shows that the optimal therapeutic strategy for patients with R/M HNSCC remains unclear. While many therapies have reported promising preliminary results, prospective clinical trials are required to support their adoption in clinical practice. In particular, it appears that immunotherapy and antibody-drug conjugates have high potential in this setting. Our review also highlights the importance of further investigation of the mechanisms underlying immunotherapy-resistant R/M HNSCC, to inform selection of optimal therapeutic strategies on an individual patient basis and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsNeoplasm Recurrence, LocalImmune Checkpoint InhibitorsHumansImmunotherapyDrug Resistance, NeoplasmB7-H1 AntigenProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Head and neck squamous cell carcinomaImmunotherapyPD-1PD-L1Resistance

Substanzen

Immune Checkpoint InhibitorsCD274 protein, humanB7-H1 AntigenProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Division of Medical Oncology, National Cancer Centre Singapore;Center for Clinician Scientist Development, SingHealth Duke-NUS, Singapore.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
  • Value & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai, China.
  • Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: pattrickguo@gmail.com.

Zitieren

APA

Tahara, M., Lim, D. W., Keam, B., Ma, B., Zhang, L., Wang, C., & Guo, Y. (2025). Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy. Cancer Treatment Reviews, 136, 102938. https://doi.org/10.1016/j.ctrv.2025.102938

Vancouver

Tahara M, Lim DW, Keam B, Ma B, Zhang L, Wang C, et al. Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy. Cancer Treatment Reviews. 2025;136:102938. doi:10.1016/j.ctrv.2025.102938

BibTeX
@article{Tahara2025,
  author = {Tahara, Makoto and Lim, Darren Wan-Teck and Keam, Bhumsuk and Ma, Brigette and Zhang, Li and Wang, Chaojun and Guo, Ye},
  title = {Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {136},
  pages = {102938},
  doi = {10.1016/j.ctrv.2025.102938}
}
Kostenlos starten →